Denis Chem Lab Ltd

Denis Chem Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent share price declines and a challenging market backdrop, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present compelling value compared to peers and historical averages.

Denis Chem Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its quality grading slip from average to below average, prompting a downgrade in its Mojo Grade from Sell to Strong Sell as of 25 Feb 2026. This shift reflects a deterioration in key business fundamentals, including returns on equity and capital employed, as well as concerns over growth consistency and leverage metrics.

Denis Chem Lab Limited, a micro-cap pharmaceutical manufacturer specialising in sterile intravenous injectables, reported a concerning fourth quarter for FY26, with net profit plummeting 81.70% quarter-on-quarter to just ₹0.40 crores from ₹3.32 crores in Q3 FY26. Despite modest revenue growth of 2.70% QoQ to ₹46.75 crores, the company's profitability collapsed as operating margins contracted sharply from 13.22% to 5.43%, raising serious questions about cost management and operational efficiency.

Denis Chem Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. Despite achieving record quarterly net sales, the company faced significant contraction in profitability metrics, prompting a downgrade in its Mojo Grade from Hold to Sell as of 25 February 2026.

Denis Chem Lab Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting a recalibration in price attractiveness amid evolving market dynamics. Despite a recent downgrade in its overall Mojo Grade to Sell, the company’s valuation metrics suggest a more compelling entry point compared to its historical and peer benchmarks within the Pharmaceuticals & Biotechnology sector.

Denis Chem Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Denis Chem Lab Ltd has witnessed a marked improvement in its valuation parameters, shifting from an attractive to a very attractive rating, despite ongoing headwinds in the Pharmaceuticals & Biotechnology sector. This recalibration in price metrics, notably the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks.

Denis Chem Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Denis Chem Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 29 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Denis Chem Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 April 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Denis Chem Lab Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting a more compelling price point for investors. Despite a recent downgrade in its overall Mojo Grade to Sell, the company’s price-to-earnings and price-to-book ratios suggest a valuation that is increasingly appealing relative to its historical averages and sector peers.

Denis Chem Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

For the seventh consecutive session, Denis Chem Lab Ltd has closed lower, culminating in a fresh 52-week low of Rs 58 on 30 Mar 2026. This marks a near 20% decline over the past week, underscoring sustained selling pressure amid a broader market downturn.

For the sixth consecutive session, Denis Chem Lab Ltd has closed lower, culminating in a fresh 52-week low of Rs 61.25 on 27 Mar 2026. This marks a 14.65% decline over the past six days, underscoring sustained selling pressure despite pockets of positive financial data.

Denis Chem Lab Ltd is rated Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 27 March 2026, providing investors with the most up-to-date analysis.

For the fifth straight session, Denis Chem Lab Ltd closed lower, breaching its 52-week low at Rs 61.36 on 25 Mar 2026, marking a 10.65% decline over this period amid a broader market rally.

For the third consecutive session, Denis Chem Lab Ltd has closed lower, culminating in a fresh 52-week low of Rs 64.1 on 23 Mar 2026. This marks an 11.27% decline over the past three days, underscoring persistent selling pressure despite some pockets of strength in the broader market.